🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TVs6b9
@ASCO

#SocialListening #LucidQuest

At #ESMO26, GI oncology experts are keeping their eye on key presentations in CRC and pancreatic cancer.

Sign up and read our preview of some of the top GI cancer abstracts to watch at the 2026 ESMO Congress in Madrid #crcsm #pancsm

www.onclive.com/view/targete...

FDA approves new treatment option, atezolizumab in combination with chemotherapy, for patients with stage III dMMR colon cancer based on results from the phase III ATOMIC trial led by Alliance. Learn more at https://bit.ly/FDA-ATOMIC #NCI #NCTN #CancerResearch #CRCsm

🚨BREAKING: The @fda.gov has approved atezolizumab in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients 2 years of age and older with stage III dMMR colon cancer #crcsm #oncology

Read more: www.onclive.com/view/fda-app...

🚨BREAKING🚨: The @fda.gov has approved atezolizumab plus chemo for the adjuvant treatment of adult and pediatric patients 2 years of age and older with stage III mismatch repair–deficient colon cancer. #crcsm #oncology

Full story ➡️: www.onclive.com/view/fda-app...

📰 The @fda.gov granted breakthrough therapy designation to telisotuzumab adizutecan plus bevacizumab for pretreated, refractory mCRC. #crcsm #oncology

Full story ➡️: www.onclive.com/view/fda-gra...

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TVk8mN
@ASCO

#SocialListening #LucidQuest

Is surgery becoming the adjuvant step in colorectal cancer?

In this episode of #OncologyUnplugged 🔌, Chandler Park, MD, and Pashtoon Kasi, MD, MS, unpack neoadjuvant immunotherapy, from NICHE to NEST, dMMR to MSS, and ctDNA as an emerging end point.

🎧 onclive.com/view/neoadju... #crcsm

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TVZrrx
@ASCO

#SocialListening #LucidQuest

📰 The @fda.gov has withdrawn the accelerated approval indication for previously treated adagrasib plus cetuximab for KRAS G12C–mutated mCRC. #crcsm #oncology

See the full story on our site ➡️: www.onclive.com/view/fda-wit...

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TVRwF2
@ASCO

#SocialListening #LucidQuest

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TVJN5b
@ASCO

#SocialListening #LucidQuest